Phenotypic and Genotypic Identification and Characterization of MYH9-related Constitutional Thrombocytopenia (MAGIC-MYH9)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2013 by Assistance Publique - Hôpitaux de Paris
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT00925236
First received: June 19, 2009
Last updated: September 2, 2013
Last verified: August 2013
  Purpose

The research involves the establishment of a cohort including as much as possible cases of macrothrombocytopenia related to a "MYH9 syndrome" and the study of mutations and polymorphisms of MYH9 gene in all these patients. As MYH9 syndrome is an autosomal dominant disorder, patients should be heterozygous for a MYH9 gene mutation.

The main goal of our project is looking for correlations between genotype and phenotype. It is planned to characterize the phenotype and genotype of a cohort of patients, including family members that will be addressed during the study in order to better understand the platelet disorder and improve the epidemiological knowledge of MYH9 syndrome. The data will be recorded in a database.


Condition
May-Hemalin
Fechtner Syndrome (Disorder)
Epstein Syndrome (Disorder)
MYH9 Related Disorders

Study Type: Observational
Study Design: Observational Model: Cohort
Official Title: Phenotypic and Genotypic Identification and Characterization of MYH9-related Constitutional Thrombocytopenia

Resource links provided by NLM:


Further study details as provided by Assistance Publique - Hôpitaux de Paris:

Primary Outcome Measures:
  • Study of the correlations phenotype - MYH9 genotype of the patients [ Time Frame: final time frame at the end of the study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • - Describe the initial clinical symptoms and the long- term evolution of MYH9-related macrothrombocytopenia - Explore the consequences of MYH9 gene mutations on the proplatelets production - Study the effects of MYH9 gene mutations on the platelet [ Time Frame: final time frame at the end of the study ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Blood sample


Estimated Enrollment: 360
Study Start Date: August 2009
Estimated Study Completion Date: July 2015
Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Detailed Description:

Definition: Extended description of the protocol, including information not already contained in other fields, such as comparison(s) studied. The patients that will participate in the study will be suffering or suspected suffering from MYH9 syndrome.

The study of MYH9 gene will be proposed to the patients but also to both parents of the propositi and other family members (children and adults), whether symptomatic or not. The relatives who will be proved to be heterozygotes for a MYH9 mutation will be considered as new cases and therefore included in the cohort of patients.

Four groups of controls (individuals who are not affected by a decrease in the platelet count) will be constituted:

A1: controls for proplatelets production study A2: controls for platelet proteome study B: controls for MYH9 gene analysis C: controls for leukocytes immunofluorescence study

Patients Patients will be included at the 6 sites of the national Reference Center for Inherited Platelet Disorders (CRPP) after signing an informed consent form. During the visit of inclusion (V1), data usually required for the diagnosis of MYH9 syndrome will be collected: clinical examination, auditory and ocular check, blood tests including MYH9 gene analysis, and search for proteinuria.

Among patients with a MYH9 mutation, a limited number will be recruited in a second step for participating to specific studies focused on the consequences of MYH9 mutations on the proplatelets production and the platelet proteome. The selected patients should be representative of the different phenotypes of MYH9 syndrome. They should be adults and have a platelet count above 50 G / L. A blood sample will be drawn for this purpose during a second visit (V2).

An annual control will be offered at year 1, year 2 and year 3 after inclusion to all the patients confirmed to have MYH9 syndrome (with MYH9 mutation). Each control will include: clinical examination and record of bleeding episodes, if any, during the past year, blood tests, search for proteinuria. The last control (end of the study) will also include auditory and ocular tests.

Relatives The relatives will be included in the study after signing informed consent form during an inclusion visit (VAP) at one of the 6 sites of CRPP. During the visit, a blood sample will be drawn for platelet and MYH9 gene study.

Controls The controls will be included in the study after signing informed consent at 6 sites of the CRPP. During their inclusion visit (VT), a blood sample will be drawn for platelet and MYH9 gene study.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

defined population

Criteria

Inclusion Criteria:

  1. Thrombocytopenia with large/giant platelets (macrothrombocytopenia=MT)
  2. and at least one of the following criteria:

    • chronicity of the MT or MT at least found at 2 successive examinations
    • Leukocyte inclusions in polymorphonuclear neutrophils
    • Juvenile sensorineural hearing loss
    • Nephritis
    • Presenile cataracts
    • Familial cases with bleeding disorder associated at least with one of the following symptoms: thrombocytopenia, nephritis, cataracts, deafness, leukocyte inclusions in polymorphonuclear neutrophils
  3. Patient who has given his consent
  4. Patient who has a social insurance -

Exclusion Criteria:

  • Other proven constitutional macrothrombocytopenia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00925236

Contacts
Contact: Nicole Schlegel, MD,PhD +33 (0) 1 40 03 23 64 nicole.schlegel@rdb.aphp.fr

Locations
France
Hôpital Robert Debré Recruiting
Paris, France, 75019
Contact: Nicole Schlegel, MD,PhD    +33 (0) 1 40 03 23 64    nicole.schlegel@rdb.aphp.fr   
Principal Investigator: Nicole Schlegel, MD,PhD         
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Principal Investigator: Nicole Schlegel, MD,PhD Assistance Publique - Hôpitaux de Paris
  More Information

No publications provided

Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT00925236     History of Changes
Other Study ID Numbers: P070110
Study First Received: June 19, 2009
Last Updated: September 2, 2013
Health Authority: France: Ministry of Health

Keywords provided by Assistance Publique - Hôpitaux de Paris:
MYH9 gene
macrothrombocytopenia
leukocyte inclusions
cataracts deafness
nephritis
MYH9 Related Disorders

Additional relevant MeSH terms:
Disease
Hearing Loss, Sensorineural
Nephrotic Syndrome
Syndrome
Thrombocytopenia
Blood Platelet Disorders
Ear Diseases
Hearing Disorders
Hearing Loss
Hematologic Diseases
Kidney Diseases
Nephrosis
Nervous System Diseases
Neurologic Manifestations
Otorhinolaryngologic Diseases
Pathologic Processes
Sensation Disorders
Signs and Symptoms
Urologic Diseases

ClinicalTrials.gov processed this record on October 21, 2014